August 27, 2020 — Machine learning and model-based drug discovery is rapidly becoming the norm. Computational biology is now integrating ‘wet’ in vitro/in vivo and ‘dry’ in silico biology accelerating and saving time and resources, at least in the early stages of drug discovery. This MassBio panel discussion explored the new world of digital biology as a way to model potential drug effects more accurately and quickly.
AI and Drug Discovery: Marrying Data Science with Core Biology
Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.
QUARTZBIO® and the PRECISION QUARTZBIO logo® are registered trademarks of Precision Medicine Group, LLC in the United States and/or other jurisdictions. All rights reserved. The names and logos of other companies and products appearing on the website may be trademarks or registered trademarks of such other companies.